TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07213830: A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic So

Sponsor: Ipsen · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 102 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07213830 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07213830 Rescue Dossier →